Eagle Asset Management’s AstraZeneca AZN Stock Holding History

Eagle Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$37.1M	Sell	287,802 -422,290	-59%	-$68.2M	0.19%	133
2024 Q2	$111M	Sell	710,092 -5,346	-0.7%	-$804K	0.59%	57
2024 Q1	$96.2M	Buy	715,438 +41,455	+6%	+$5.49M	0.49%	77
2023 Q4	$90.8M	Sell	673,983 -298,502	-31%	-$38.8M	0.49%	85
2023 Q3	$132M	Buy	972,485 +175,739	+22%	+$24M	0.78%	33
2023 Q2	$114M	Sell	796,746 -29,793	-4%	-$4.38M	0.64%	52
2023 Q1	$115M	Sell	826,539 -6,417	-0.8%	-$863K	0.67%	54
2022 Q4	$115M	Sell	832,956 -69,979	-8%	-$8.78M	0.71%	41
2022 Q3	$99M	Buy	902,935 +79,935	+10%	+$10.1M	0.65%	47
2022 Q2	$109M	Buy	823,000 +1,232	+0.1%	+$162K	0.68%	38
2022 Q1	$109M	Buy	821,768 +84,949	+12%	+$10.2M	0.56%	62
2021 Q4	$86.2M	Sell	736,819 -6,494	-0.9%	-$764K	0.38%	99
2021 Q3	$89.3M	Buy	743,313 +735,750	+9,728%	+$85.6M	0.4%	93
2021 Q2	$906K	Buy	7,563 +571	+8%	+$62.6K	﹤0.01%	516
2021 Q1	$692K	Buy	6,992 +4,597	+192%	+$462K	﹤0.01%	524
2020 Q4	$239K	Sell	2,395 -4,299	-64%	-$455K	﹤0.01%	498
2020 Q3	$737K	Sell	6,694 -289	-4%	-$32.1K	﹤0.01%	493
2020 Q2	$738K	Buy	+6,983	New	+$721K	﹤0.01%	501

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Eagle Asset Management's AZN Position: Q3 2024 in Review

Eagle Asset Management reduced its AstraZeneca (AZN) stake by 59% in Q3 2024, selling an estimated $68.2M and leaving 287,802 shares worth $37.1M. The position accounts for 0.19% of the portfolio, ranked #133.

Eagle Asset Management first reported a position in AZN in Q2 2020 and has held it in 18 quarters since. The position peaked at $132M in Q3 2023. 1,230 funds tracked by Wall St. Rank hold AZN as of Q3 2024.

Eagle Asset Management held 287,802 shares of AstraZeneca worth $37.1M as of Q3 2024.
Eagle Asset Management sold 422,290 AstraZeneca shares in Q3 2024, an estimated $68.2M.
AstraZeneca made up 0.19% of Eagle Asset Management's portfolio in Q3 2024, its #133 holding.
Eagle Asset Management first reported a position in AstraZeneca in Q2 2020 and has held it in 18 quarters since.
Eagle Asset Management's AstraZeneca position peaked at $132M in Q3 2023.
1,230 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2024.

Based on Eagle Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.